



**PETER K. KAISER, MD**  
Medical Advisor, Retina Today;  
Cole Eye Institute, Cleveland, OH

View Interactive  
Version Online



If you would like to submit an addition for next year's poster, please email Peter K. Kaiser, MD, at [pkkaiser@gmail.com](mailto:pkkaiser@gmail.com) and Cara Deming at [cdeming@bmcctoday.com](mailto:cdeming@bmcctoday.com).

**RT**  
Retina Today

**RETINA PIPELINE 2026**  
A VIEW INTO ONGOING  
INNOVATION **WET AMD**

## Extracellular VEGF Pathways

- VEGF**  
PIGF C/D B A
- pegaptanib (Bausch + Lomb) **FDA APPROVED**
  - Port Delivery System (Genentech/Roche) **FDA APPROVED**
  - ranibizumab (Genentech/Roche) **FDA APPROVED**
  - ranibizumab-nuna (Samsung/Biogen) **FDA APPROVED**
  - ranibizumab-eqrn (Sandoz) **FDA APPROVED**
  - ranibizumab-Ximluci (Xbrane Biopharma) **EMA APPROVED**
  - ranibizumab-Ranivisio (Teva) **EMA APPROVED**
  - ranibizumab-RanizuRel (Reliance Life Sciences) **INDIA FDA APPROVED**
  - ranibizumab-Razumab (Intas Pharmaceuticals) **INDIA FDA APPROVED**
  - ranibizumab-leyk (Formycon/Bioeq)
  - LUBT010 (Lupin Ltd/Amman)
  - SCT520FF (SinoCellTech)
  - SJP1-0133 (Senju Pharmaceutical)
  - BCD100 (BIOCND/Qilu)
  - CKD-701 (Chong Kun Dang)
  - biosimilars to ranibizumab
  - bevacizumab
  - bevacizumab-vikg (Outlook Therapeutics) **EMA/UK APPROVED**
  - TAB014 (Zhaoke Ophthalmology)
  - CT-P16 (Celltrion)
  - alymys (Amneal Pharmaceuticals/mAbxience)
  - EB12-20145P (EssexBio)
  - AK-3008 (Anhui Anke Biotechnology)
  - MIL-60 (Beijing Mabworks Biotech)
  - biosimilars to bevacizumab
  - brlucizumab (Novartis) **FDA APPROVED**
  - abicipar pegol (Molecular Partners)
  - KNP-301 (Kanaph Therapeutics)
  - tarcoicimab tedromer (Kodiak Sciences) **PIVOTAL STUDY**
  - VLTR-559 (Valitor) — Multivalent Polymer Conjugation
  - high-dose aflibercept (Regeneron) **FDA APPROVED**
  - aflibercept (Regeneron) **FDA APPROVED**
  - aflibercept-ayyh (Amgen) **FDA APPROVED**
  - aflibercept-jbvf (Biocon) **FDA APPROVED**
  - aflibercept-yszy (Samsung/Biogen) **FDA APPROVED**
  - aflibercept-abzv (Sandoz) **FDA APPROVED**
  - aflibercept-mrbb (Formycon) **FDA APPROVED**
  - aflibercept-boav (Celltrion) **FDA APPROVED**
  - ALT-L9 (Altas Biologics)
  - MYL-1701 (Mylan/Momenta)
  - RBS-001 (Rophibia)
  - SCD411 (Sam Chun Dang Pharmaceutical Co./Fresenius Kabi)
  - OT-702 (Ocumension Therapeutics/Shandong Boan)
  - AVT-06 (Alvotect)
  - conbercept (Kanghong Biotech) **CDE APPROVED**
  - IBI302 (Innovent Biologics) — Plus CR1 Inhibition
  - IBI333 (Innovent Biologics)
  - TH103 (Kalaris Therapeutics) — VEGFR1 domain3 + heparin-binding proteins
  - OPT-640 (OptigoBio)

Editorially independent content supported by advertising from Genentech

## TIE2 Activation Pathways

- faricimab (Genentech/Roche) **FDA APPROVED**
- BI 836880 (Boehringer Ingelheim)
- VIS-101 (Visara)
- ABP-201 (AbPro)
- OLN324 (Ollin Biosciences)
- zifibancimig (Roche)
- RO-104 (RevOpsis)
- EB-105 (Eluminex Biosciences)
- AM-712 (AffaMed Therapeutics)
- PMC-403 (PharmAbcine) — TIE2 Activating MAB
- tiespectus (Merck/EyeBio) — TIE2 Activating bi-specific
- IGT-427 (Ingenia Therapeutics/Mosaic) — TIE2 Activating/anti-VEGF

## Integrin Pathways

- PAN**
- risuteganib (Allegro/Affamed/Hanmi)
  - OCU200 (Ocugen) — Tumstatin and Transferrin Fusion Protein
  - AG-73305 (Allgenesis Biotherapeutics)
  - gersizangitide (AsclepiX Therapeutics)

## Gene Therapy

- RGX-314 (Regenxbio/AbbVie) **PIVOTAL STUDY**
- AL-001 (Beijing Along Biopharmaceutical Co)
- HG202 (HuidaGene Therapeutics Co)
- ixoberogene soroparvovec (Adverum Biotechnologies) **PIVOTAL STUDY**
- NG101 (Neuraclie Genetics)
- LX102 (InnoStellar Biotherapeutics)
- E301 (Samsung)
- FT-003 (Frontera)
- ABI-t10 (Avirmax Biopharma)
- 4D-150 (4D Molecular Therapeutics) **PIVOTAL STUDY**
- EXG102-031 (Exegenesis Bio)
- KH631 (Kanghong Biotech)
- KH658 (Vanotech)
- HG202 (HuidaGene Therapeutics) — CRISPR/Cas13 RNA VEGF Editing
- BD311 (Shanghai BDgene Therapeutics Co)
- SKG0106 (Skyline Therapeutics)
- RRG001 (Refreshgene)
- IVB103 (InnoVec Biotherapeutics)
- PST-809 (PulseSight Therapeutics) — Non-Viral Anti-VEGF with Decorin Plasmid
- SAR402663 (Sanofi)
- AL-001 (Beijing Anlong Biopharmaceutical Co)
- CoTx-101 (Coave Therapeutics)

## Other Pathways

- CVX-51401 (CavtheRx) — Caveolin Modulator
- EXN407 (Exonate/Janssen) — SRPK1 Inhibitor
- aganirsen (Gene Signal) — Inhibition of Insulin Receptor Substrate 1 (IRS-1)
- PL9654 (Palatin Technologies) — Melanocortin Receptor Agonist
- foselutoclast (Unity Biotechnology) — Bcl-xL Inhibitor
- EOM147 (EOM Pharmaceuticals) — Squalamine Analog
- ISTH0036 (Isarna Therapeutics) — TGF-Beta2 Antisense Oligonucleotide
- ATX-9874 (Augen/Duet Therapeutics) — Indoleamine 2,3-dioxygenase (IDO) Inhibitor
- CU06 (Curacle/Thea) — Block cAMP/Cortactin Pathway
- OLX-301D (OliX) — cp-asiRNA-CTGF/CCN2 Inhibitor
- umedaptanib pegol (Ribomic) — FGF2 Inhibitor
- RC28-E (RemeGen) — FGF2/VEGF Inhibitor **PIVOTAL STUDY**
- CG-P5 (Caregen) — CG-P5 Peptide
- OGX-110 (Ocugenix) — CXCR3 Chemokine Receptor 3 Agonist
- BBC1501 (BenoBio) — Targets BET (bromodomain and extra-terminal) Proteins
- ABF-101/103 (AptaBio) — Nox Inhibitor
- OCUL101 (Ocugen) — Anti-VEGF/C5

## Interleukin Pathways



- KSI-501 (Kodiak Sciences) — Anti-VEGF/IL6 Antibody Polymer Conjugate (ABC) **PIVOTAL STUDY**
- KSI-101 (Kodiak Sciences) — Anti-IL6/VEGF
- SZN-8143 (Surrozen) — Anti-IL6/anti-VEGF/Fzd4 Agonist
- LNR-653.1 (Lanier Biotherapeutics) — Anti-IL17A/VEGF
- RO7497372 (Genentech) — Anti-IL6/VEGF

## Tyrosine Kinase Inhibitors (TKI)

- Axpaxli/axitinib (Ocular Therapeutix) **PIVOTAL STUDY**
- AR-14034/axitinib (Alcon/Aerie)
- Duravyu/vorolanib (EyePoint Pharmaceuticals) **PIVOTAL STUDY**
- AIV007/lenvatinib (AiViva Biopharma)
- D-4517.2/migalidendrinib / sunitinib analog (Ashvattha Therapeutics)
- KPI-287 (Kala Pharmaceuticals)
- TO-0-1002 (TheratOcular Biotek Co., Ltd.)
- PAN 90806 (PanOptica)
- KHK4951/tivozanib (Kyowa Kirin Group)
- HX9428 (Fujian Haixi Pharmaceuticals)

## WNT Pathways

- SYL-1801 (Sylentis) — siRNA Nrarp Inhibitor
- MK-3000 (EyeBio/Merck) — WNT Agonist
- SZN-413 (Surrozen) — Fzd4 Agonist
- SZN-8141 (Surrozen) — Fzd4 Agonist/Anti-VEGF



**VABYSMO**  
faricimab-svoa injection 6 mg

IT'S NOT JUST DATA  
IT'S REAL-WORLD RESULTS

DISCOVER HOW OUR REAL-WORLD DATA  
MAKES A REAL DIFFERENCE



SCAN TO  
EXPLORE FARETINA

**Genentech**  
A Member of the Roche Group

**CHOOSE  
VABYSMO®  
FIRST**